Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | SMO | Q99835 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 12/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361914 | 0.85 | CYP11B1 (0.54) | CYP11B1CYP11B2SMOMAPK1NR3C1 | |
| SCHEMBL1362100 | 0.79 | NR3C1 (0.53) | SMOMAPK1NR3C1PGR | |
| SCHEMBL1362299 | 0.78 | SMO (0.50) | SMOMAPK1NR3C1PGR | |
| SCHEMBL1363389 | 0.77 | CYP11B1 (0.69) | CYP11B1CYP11B2SMONR3C1PGR | |
| SCHEMBL20167005 | 0.77 | CYP11B1 (0.59) | CYP11B1CYP11B2SMOMAPK1NR3C1 | |
| SCHEMBL1362733 | 0.76 | SMO (0.55) | SMOMAPK1NR3C1PGR | |
| SCHEMBL1362699 | 0.74 | SMO (0.50) | SMOMAPK1NR3C1 | |
| SCHEMBL15826159 | 0.73 | NR3C1 (0.51) | SMOMAPK1NR3C1PGR | |
| SCHEMBL1363292 | 0.73 | NR3C1 (0.52) | NR3C1PGR | |
| SCHEMBL1135667 | 0.72 | CCR1 (0.66) | CYP11B1CYP11B2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067447-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100076014-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| EP-2094692-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008057856-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076014-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKBIA, NFKB1 | CYP11B1 75/4885CYP11B2 163/4885SMO 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.